瑞典真实世界环境中贝利尤单抗浓度与免疫原性及其与SLE药物有效性和安全性的关系
研究纳入100例接受静脉贝利尤单抗治疗的SLE患者,在基线及第3、6、12、24个月采集临床数据和生物样本,检测贝利尤单抗浓度和抗药物抗体(ADA)。结果显示贝利尤单抗无免疫原性,药物浓度与临床活动度呈轻度关联,但与血清学活动或不良事件无关联。
要点
- 100例静脉贝利尤单抗治疗的SLE患者中,2例检出预存ADA,随访期间无患者新发ADA。
- 贝利尤单抗浓度中位数25.8 μg/ml(IQR 20.9-43.5),组水平随时间稳定。
- 贝利尤单抗浓度与临床活动度呈轻度关联,但与血清学活动及不良事件无关联。
核心结论
- 贝利尤单抗未产生免疫原性。
- 贝利尤单抗浓度与临床活动度呈轻度关联,但与血清学活动或不良事件无关联。
研究设计与样本
- 纳入100例接受静脉贝利尤单抗治疗的SLE患者,在基线及第3、6、12、24个月采集临床数据和生物样本。
- 贝利尤单抗浓度采用定量夹心ELISA测定,ADA采用酸解离放射免疫分析法检测。
- 临床活动度采用SLEDAI-2000(SLEDAI-2K)、修订版SLE活动度测量(SLAM-R)和医生整体评估(PhGA)评价。
- 血清学标志物包括C3、C4和抗dsDNA。
- 采用横断面Spearman秩相关分析和广义估计方程进行纵向分析。
主要发现
- 贝利尤单抗浓度变异较大(中位数25.8;四分位距[IQR] 20.9-43.5 μg/ml),但在组水平随时间稳定。
- 2例患者检出预存ADA,随访期间无患者新发ADA。
- 第6个月贝利尤单抗浓度与SLEDAI-2K(ρ:-0.37;P=0.003)和PhGA(ρ:-0.41;P=0.005)呈中度相关。
- 纵向分析显示贝利尤单抗浓度与SLEDAI-2K关联极弱(β:-0.10;SE:0.05;P=0.031),与SLAM-R关联较弱(β:-0.32;SE:0.13;P=0.014)。
- 第6个月贝利尤单抗浓度与血清学标志物呈中度相关,但纵向分析中无关联;贝利尤单抗浓度与不良事件无关系。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Studies supporting therapeutic drug monitoring to biopharmaceuticals in SLE are scarce. We aimed to assess anti-drug antibody (ADA) occurrence in belimumab-treated SLE patients and associations between belimumab concentrations and clinical response, serological outcomes and adverse events. METHODS: We included 100 patients treated with intravenous belimumab. Clinical data and biological samples were collected at baseline and months 3, 6, 12 and 24. Belimumab levels were determined by quantitative sandwich ELISA, and ADA by an acid-dissociation radioimmunoassay. Clinical activity was evaluated with the SLEDAI-2000 (SLEDAI-2K), revised SLE activity measure (SLAM-R) and physician's global assessment (PhGA). Serological markers included C3, C4 and anti-dsDNA. We performed cross-sectional Spearman's rank correlation analyses, and longitudinal analyses using generalized estimating equations. RESULTS: Belimumab concentrations varied widely (median: 25.8; interquartile range [IQR]: 20.9-43.5 μg/ml) but were stable over time at the group level. Pre-existing ADA was detected in two patients, but no patient developed ADA during follow-up. Belimumab levels moderately correlated with SLEDAI-2K (ρ: -0.37; P = 0.003) and PhGA (ρ: -0.41; P = 0.005) at month 6, while longitudinal analysis revealed a very weak association with SLEDAI-2K (β: -0.10; SE: 0.05; P = 0.031) and a weak association with SLAM-R (β: -0.32; SE: 0.13; P = 0.014). Despite moderate correlations between belimumab levels and serological markers at month 6, there were no associations in longitudinal analysis. There was no relationship between belimumab levels and adverse events. CONCLUSION: Belimumab yielded no immunogenicity. Belimumab levels were modestly associated with clinical activity but not with serological activity or adverse events.
引用
- Gomez A, Walhelm T, Loeff FC, et al. Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting. Rheumatology (Oxford). 2025. PMID: 40037576. doi:10.1093/rheumatology/keaf128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。